D
Dietmar Krex
Researcher at Dresden University of Technology
Publications - 112
Citations - 7872
Dietmar Krex is an academic researcher from Dresden University of Technology. The author has contributed to research in topics: Temozolomide & Glioma. The author has an hindex of 37, co-authored 101 publications receiving 6572 citations. Previous affiliations of Dietmar Krex include German Cancer Research Center.
Papers
More filters
Journal ArticleDOI
Long-term survival with glioblastoma multiforme
Dietmar Krex,Barbara Klink,Christian Hartmann,Andreas von Deimling,Torsten Pietsch,Matthias Simon,Michael Sabel,Joachim P. Steinbach,Oliver Heese,Guido Reifenberger,Michael Weller,Gabriele Schackert +11 more
TL;DR: The association of glioblastoma long-term survival with prognostically favourable clinical factors, in particular young age and good initial performance score, as well as MGMT promoter hypermethylation is underline.
Journal ArticleDOI
European Stroke Initiative Recommendations for Stroke Management-update 2003.
Gunnel Carlsson,Anders Möller,Christian Blomstrand,Takashi Ueda,Katsufumi Mizushige,Kazushi Yukiiri,Tsutomu Takahashi,Masakazu Kohno,Terry B.J. Kuo,Chang-Ming Chern,Cheryl C.H. Yang,Hung-Yi Hsu,Wen-Jang Wong,Wen-Yung Sheng,Han-Hwa Hu,Antonio Di Carlo,Domenico Inzitari,Franco Galati,Marzia Baldereschi,Vincenzo Giunta,Gaetano Grillo,Alfonso Furchì,Valerio Manno,Francesco Naso,Antonino Vecchio,Domenico Consoli,Yong Jeong,Gyeong-Moon Kim,Young Min Song,Duk L. Na,A. Montavont,N. Nighoghossian,Marc Hermier,Laurent Derex,Yves Berthezène,E. Philippeau,Jérôme Honnorat,Jean-Claude Froment,Louis R. Caplan,Paul Trouillas,B. Ogungbo,B. Gregson,A.D. Mendelow,E. Stolz,C. Klötzsch,A. Rahimi,F. Schlachetzki,M. Kaps,Louise Martinsson,Staffan Eksborg,Nils Wahlgren,José M. Ferro,A.J. Steck,Dietmar Krex,Andreas Ziegler,Inke R. König,Hans K. Schackert,Gabriele Schackert,Karin Rossnagel,Jacqueline Müller-Nordhorn,Michael Kulig,Stefan N. Willich,A. Triquenot-Bagan,E. Gerardin,E. Guegan-Massardier,Y. Onnient,F. Leroy,B. Mihout,J.F. Weber,E. Kirsch,E.W. Radü,H.J. Kaiser,Ph.A. Lyrer,Shuzo Shintani,Shin Tsuruoka,Tatsuo Shiigai,Kenji Ishii,Adrià Arboix,Montserrat Oliveres,Luis García-Eroles,Emili Comes,Miquel Balcells,Cecilia Targa,Jae-Kwan Cha,Min-Ho Jeong,Ji-Yeon Jang,Hae-Rahn Bae,Yeong-Jin Lim,Jung Sun Kim,Sang-Ho Kim,Jae Woo Kim,Ynte M. Ruigrok,Ale Algra,Gabriel J.E. Rinkel,David Quartermain,Yong Sheng Li,Saran Jonas,Eduardo Martínez-Vila,José A. Páramo,Oscar Beloqui,Josune Orbe,Pablo Irimia,Inmaculada Colina,Ignacio Monreal,Alberto Benito,Joaquin Barba,José L. Zubieta,Javier Díez,Siviero Agazzi,Philippe Maeder,Jean-Guy Villemure,Luca Regli,J K Lovett,Peter M. Rothwell,Josef G. Heckmann,Clive M. Brown,Michaela Cheregi,Max J. Hilz,Bernhard Neundörfer,Simona Sacco,Alfredo Dragani,Giovanni Davì,Antonio Carolei +122 more
TL;DR: This article represents the update of ‘European Stroke Initiative Recommendations for Stroke Management’, first published in this Journal in 2000.
Journal ArticleDOI
Molecular Predictors of Progression-Free and Overall Survival in Patients With Newly Diagnosed Glioblastoma: A Prospective Translational Study of the German Glioma Network
Michael Weller,Jörg Felsberg,Christian Hartmann,Hilmar Berger,Joachim P. Steinbach,Johannes Schramm,Manfred Westphal,Gabriele Schackert,Matthias Simon,Jörg C. Tonn,Oliver Heese,Dietmar Krex,Guido Nikkhah,Torsten Pietsch,Otmar D. Wiestler,Guido Reifenberger,Andreas von Deimling,Markus Loeffler +17 more
TL;DR: Molecular changes associated with gliomagenesis do not predict response to therapy in glioblastoma patients managed according to current standards of care and MGMT promoter methylation and IDH1 mutational status allow for stratification into prognostically distinct subgroups.
Journal ArticleDOI
5-Hydroxymethylcytosine Is Strongly Depleted in Human Cancers but Its Levels Do Not Correlate with IDH1 Mutations
Seung-Gi Jin,Yong Jiang,Runxiang Qiu,Tibor A. Rauch,Yinsheng Wang,Gabriele Schackert,Dietmar Krex,Qiang Lu,Gerd P. Pfeifer +8 more
TL;DR: The data suggest that 5hmdC is strongly depleted in human malignant tumors, a finding that adds another layer of complexity to the aberrant epigenome found in cancer tissue, and a lack of 5hmC may become a useful biomarker for cancer diagnosis.
Journal ArticleDOI
First results on survival from a large Phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastoma.
Linda M. Liau,Keyoumars Ashkan,David Tran,Jian Campian,John E. Trusheim,Charles S. Cobbs,Jason Heth,Michael Salacz,Sarah A. Taylor,Stacy D. D’Andre,Fabio M. Iwamoto,Edward J. Dropcho,Yaron A. Moshel,Kevin A. Walter,Clement Pillainayagam,Robert Aiken,Rekha Chaudhary,Samuel Goldlust,Daniela A. Bota,Paul Duic,Jai Grewal,Heinrich Elinzano,Steven A. Toms,Kevin O. Lillehei,Tom Mikkelsen,Tobias Walbert,Steven R. Abram,Andrew Brenner,Steven Brem,Matthew G. Ewend,Simon Khagi,Jana Portnow,Lyndon Kim,William G. Loudon,Reid C. Thompson,David Avigan,Karen Fink,Francois J. Geoffroy,Scott Lindhorst,Jose Lutzky,Andrew E. Sloan,Gabriele Schackert,Dietmar Krex,Hans-Jorg Meisel,Julian Wu,Raphael P. Davis,Christopher Duma,Arnold B. Etame,David Mathieu,Santosh Kesari,David Piccioni,Manfred Westphal,David S. Baskin,Pamela Z. New,Michel Lacroix,Sven-Axel May,Timothy J. Pluard,Victor Tse,Richard M. Green,John L. Villano,Michael Pearlman,Kevin Petrecca,Michael Schulder,Lynne Taylor,Anthony E. Maida,Robert M. Prins,Timothy F. Cloughesy,Paul Mulholland,Marnix L. Bosch +68 more
TL;DR: Addition of DCVax-L to standard therapy is feasible and safe in glioblastoma patients, and may extend survival, and overall adverse events withDCVax were comparable to standard Therapy alone.